Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production

In vitro erythroid differentiation from primary human cells is valuable to develop genetic strategies for hemoglobin disorders. However, current erythroid differentiation methods are encumbered by modest transduction rates and high baseline fetal hemoglobin production. In this study, we sought to im...

Full description

Bibliographic Details
Main Authors: Naoya Uchida, Selami Demirci, Juan J. Haro-Mora, Atsushi Fujita, Lydia N. Raines, Matthew M. Hsieh, John F. Tisdale
Format: Article
Language:English
Published: Elsevier 2018-06-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050118300366
id doaj-36b473ce1996481989274e0c3f7ae7cf
record_format Article
spelling doaj-36b473ce1996481989274e0c3f7ae7cf2020-11-24T22:13:48ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012018-06-019247256Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin ProductionNaoya Uchida0Selami Demirci1Juan J. Haro-Mora2Atsushi Fujita3Lydia N. Raines4Matthew M. Hsieh5John F. Tisdale6Sickle Cell Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA; Corresponding author: Naoya Uchida, Sickle Cell Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, 9000 Rockville Pike, Building 10, 9N112, Bethesda, MD 20892, USA.Sickle Cell Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USASickle Cell Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USASickle Cell Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USASickle Cell Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USASickle Cell Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USASickle Cell Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USAIn vitro erythroid differentiation from primary human cells is valuable to develop genetic strategies for hemoglobin disorders. However, current erythroid differentiation methods are encumbered by modest transduction rates and high baseline fetal hemoglobin production. In this study, we sought to improve both genetic modification and hemoglobin production among human erythroid cells in vitro. To model therapeutic strategies, we transduced human CD34+ cells and peripheral blood mononuclear cells (PBMCs) with lentiviral vectors and compared erythropoietin-based erythroid differentiation using fetal-bovine-serum-containing media and serum-free media. We observed more efficient transduction (85%–93%) in serum-free media than serum-containing media (20%–69%), whereas the addition of knockout serum replacement (KSR) was required for serum-free media to promote efficient erythroid differentiation (96%). High-level adult hemoglobin production detectable by electrophoresis was achieved using serum-free media similar to serum-containing media. Importantly, low fetal hemoglobin production was observed in the optimized serum-free media. Using KSR-containing, serum-free erythroid differentiation media, therapeutic adult hemoglobin production was detected at protein levels with β-globin lentiviral transduction in both CD34+ cells and PBMCs from sickle cell disease subjects. Our in vitro erythroid differentiation system provides a practical evaluation platform for adult hemoglobin production among human erythroid cells following genetic manipulation. Keywords: lentiviral vector, hematopoietic stem cells, erythroid cells, erythroid differentiation, adult hemoglobin, gene therapy, genome editinghttp://www.sciencedirect.com/science/article/pii/S2329050118300366
collection DOAJ
language English
format Article
sources DOAJ
author Naoya Uchida
Selami Demirci
Juan J. Haro-Mora
Atsushi Fujita
Lydia N. Raines
Matthew M. Hsieh
John F. Tisdale
spellingShingle Naoya Uchida
Selami Demirci
Juan J. Haro-Mora
Atsushi Fujita
Lydia N. Raines
Matthew M. Hsieh
John F. Tisdale
Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production
Molecular Therapy: Methods & Clinical Development
author_facet Naoya Uchida
Selami Demirci
Juan J. Haro-Mora
Atsushi Fujita
Lydia N. Raines
Matthew M. Hsieh
John F. Tisdale
author_sort Naoya Uchida
title Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production
title_short Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production
title_full Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production
title_fullStr Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production
title_full_unstemmed Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production
title_sort serum-free erythroid differentiation for efficient genetic modification and high-level adult hemoglobin production
publisher Elsevier
series Molecular Therapy: Methods & Clinical Development
issn 2329-0501
publishDate 2018-06-01
description In vitro erythroid differentiation from primary human cells is valuable to develop genetic strategies for hemoglobin disorders. However, current erythroid differentiation methods are encumbered by modest transduction rates and high baseline fetal hemoglobin production. In this study, we sought to improve both genetic modification and hemoglobin production among human erythroid cells in vitro. To model therapeutic strategies, we transduced human CD34+ cells and peripheral blood mononuclear cells (PBMCs) with lentiviral vectors and compared erythropoietin-based erythroid differentiation using fetal-bovine-serum-containing media and serum-free media. We observed more efficient transduction (85%–93%) in serum-free media than serum-containing media (20%–69%), whereas the addition of knockout serum replacement (KSR) was required for serum-free media to promote efficient erythroid differentiation (96%). High-level adult hemoglobin production detectable by electrophoresis was achieved using serum-free media similar to serum-containing media. Importantly, low fetal hemoglobin production was observed in the optimized serum-free media. Using KSR-containing, serum-free erythroid differentiation media, therapeutic adult hemoglobin production was detected at protein levels with β-globin lentiviral transduction in both CD34+ cells and PBMCs from sickle cell disease subjects. Our in vitro erythroid differentiation system provides a practical evaluation platform for adult hemoglobin production among human erythroid cells following genetic manipulation. Keywords: lentiviral vector, hematopoietic stem cells, erythroid cells, erythroid differentiation, adult hemoglobin, gene therapy, genome editing
url http://www.sciencedirect.com/science/article/pii/S2329050118300366
work_keys_str_mv AT naoyauchida serumfreeerythroiddifferentiationforefficientgeneticmodificationandhighleveladulthemoglobinproduction
AT selamidemirci serumfreeerythroiddifferentiationforefficientgeneticmodificationandhighleveladulthemoglobinproduction
AT juanjharomora serumfreeerythroiddifferentiationforefficientgeneticmodificationandhighleveladulthemoglobinproduction
AT atsushifujita serumfreeerythroiddifferentiationforefficientgeneticmodificationandhighleveladulthemoglobinproduction
AT lydianraines serumfreeerythroiddifferentiationforefficientgeneticmodificationandhighleveladulthemoglobinproduction
AT matthewmhsieh serumfreeerythroiddifferentiationforefficientgeneticmodificationandhighleveladulthemoglobinproduction
AT johnftisdale serumfreeerythroiddifferentiationforefficientgeneticmodificationandhighleveladulthemoglobinproduction
_version_ 1725799862223503360